Patents by Inventor Jennifer L Craigen

Jennifer L Craigen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230137032
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: July 12, 2022
    Publication date: May 4, 2023
    Inventors: Paul ALGATE, Stephanie Jane CLEGG, Jennifer L. CRAIGEN, Paul Andrew HAMBLIN, Alan Peter LEWIS, Patrick MAYES, Radha Shah PARMAR, Trevor Anthony Kenneth WATTAM
  • Patent number: 11419945
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: August 23, 2022
    Assignee: GLAXO GROUP LIMITED
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Publication number: 20200197529
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 25, 2020
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Publication number: 20180147293
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: December 1, 2017
    Publication date: May 31, 2018
    Inventors: PAUL ALGATE, STEPHANIE JANE CLEGG, JENNIFER L. CRAIGEN, PAUL ANDREW HAMBLIN, ALAN PETER LEWIS, PATRICK MAYES, RADHA SHAH PARMAR, TREVOR ANTHONY KENNETH WATTAM
  • Publication number: 20160193358
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 7, 2016
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Patent number: 9273141
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 1, 2016
    Assignee: Glaxo Group Limited
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Publication number: 20140105915
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 17, 2014
    Applicant: Glaxo Group Limited
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Publication number: 20080145375
    Abstract: The present invention relates to improved nucleic acid vaccines, adjuvant systems, and processes for the preparation of such vaccines and adjuvant systems. In particular, the nucleic acid vaccines and adjuvant systems of the present invention comprise a combination of a nucleotide sequence encoding GM-CSF, or derivatives thereof, and toll-like receptor (TLR) agonists, or derivatives thereof.
    Type: Application
    Filed: September 13, 2004
    Publication date: June 19, 2008
    Applicant: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Jennifer L Craigen